QQQ   306.49 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
QQQ   306.49 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
QQQ   306.49 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
QQQ   306.49 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
NASDAQ:CLVS

Clovis Oncology - CLVS Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.08
$0.10
50-Day Range
$0.08
$1.09
52-Week Range
$0.08
$3.32
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLVS vs. RGLS, CBIO, INFI, MTEM, ADIL, LMNL, DFFN, LABP, PULM, and APGN

Should you be buying Clovis Oncology stock or one of its competitors? The main competitors of Clovis Oncology include Regulus Therapeutics (RGLS), Catalyst Biosciences (CBIO), Infinity Pharmaceuticals (INFI), Molecular Templates (MTEM), Adial Pharmaceuticals (ADIL), Liminal BioSciences (LMNL), Diffusion Pharmaceuticals (DFFN), Landos Biopharma (LABP), Pulmatrix (PULM), and Apexigen (APGN). These companies are all part of the "pharmaceutical preparations" industry.

Clovis Oncology vs.

Regulus Therapeutics (NASDAQ:RGLS) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Regulus Therapeutics has a net margin of 0.00% compared to Clovis Oncology's net margin of -189.37%. Clovis Oncology's return on equity of 0.00% beat Regulus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Regulus Therapeutics N/A -68.85% -52.91%
Clovis Oncology -189.37% N/A -57.78%

In the previous week, Regulus Therapeutics had 6 more articles in the media than Clovis Oncology. MarketBeat recorded 7 mentions for Regulus Therapeutics and 1 mentions for Clovis Oncology. Regulus Therapeutics' average media sentiment score of 1.02 beat Clovis Oncology's score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regulus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Clovis Oncology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Regulus Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Clovis Oncology received 109 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. However, 67.91% of users gave Regulus Therapeutics an outperform vote while only 65.58% of users gave Clovis Oncology an outperform vote.

CompanyUnderperformOutperform
Regulus TherapeuticsOutperform Votes
472
67.91%
Underperform Votes
223
32.09%
Clovis OncologyOutperform Votes
581
65.58%
Underperform Votes
305
34.42%

Regulus Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 971.43%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regulus Therapeutics is more favorable than Clovis Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regulus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Clovis Oncology
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

55.5% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 24.5% of Clovis Oncology shares are held by institutional investors. 8.3% of Regulus Therapeutics shares are held by company insiders. Comparatively, 4.4% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Regulus Therapeutics has higher earnings, but lower revenue than Clovis Oncology. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regulus Therapeutics$10.01 million1.41-$28.32 million-$1.90-0.44
Clovis Oncology$148.76 million0.08-$264.52 million-$1.83-0.04

Summary

Regulus Therapeutics beats Clovis Oncology on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVS vs. The Competition

MetricClovis OncologyPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$11.60M$5.54B$4.35B$5.79B
Dividend YieldN/A2.62%2.41%4.51%
P/E Ratio-0.044.4984.8212.15
Price / Sales0.08280.533,414.7756.69
Price / CashN/A18.0719.6258.02
Price / Book-0.044.304.525.05
Net Income-$264.52M$185.37M$114.61M$190.78M

Clovis Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGLS
Regulus Therapeutics
1.7932 of 5 stars
$1.04
-1.0%
$9.00
+765.4%
-71.7%$15.22M$10.01M-0.4726Positive News
CBIO
Catalyst Biosciences
0 of 5 stars
$0.20
+5.2%
N/A-70.8%$6.42M$3.23M-0.7856Upcoming Earnings
Short Interest ↑
News Coverage
Gap Up
INFI
Infinity Pharmaceuticals
1.9937 of 5 stars
$0.20
flat
$2.83
+1,316.7%
-81.5%$18.04M$2.50M-0.3823Upcoming Earnings
Analyst Report
Short Interest ↓
News Coverage
Gap Up
MTEM
Molecular Templates
2.2723 of 5 stars
$0.35
flat
$3.83
+1,004.7%
-87.3%$19.55M$35.11M-0.24261Short Interest ↑
ADIL
Adial Pharmaceuticals
2.0039 of 5 stars
$0.40
-2.4%
$3.00
+642.9%
-81.4%$11.52MN/A-0.5916Short Interest ↑
Positive News
LMNL
Liminal BioSciences
0 of 5 stars
$3.81
-4.8%
N/A-63.3%$11.81M$310,000.0076.22251Short Interest ↓
Gap Down
DFFN
Diffusion Pharmaceuticals
1.9013 of 5 stars
$5.84
-2.2%
$9.50
+62.7%
-61.5%$11.91MN/A-0.7616Analyst Report
Short Interest ↓
News Coverage
LABP
Landos Biopharma
2.0574 of 5 stars
$0.30
+15.6%
$6.00
+1,927.0%
-84.3%$11.92M$18M-0.2246Short Interest ↓
News Coverage
Gap Down
PULM
Pulmatrix
1.9229 of 5 stars
$3.06
+1.0%
$10.00
+226.8%
-56.0%$11.14M$5.17M0.0024Upcoming Earnings
News Coverage
Gap Up
APGN
Apexigen
1.5104 of 5 stars
$0.50
-20.7%
$11.50
+2,213.0%
N/A$12.25MN/A0.00N/APositive News
This page (NASDAQ:CLVS) was last updated on 3/28/2023 by MarketBeat.com Staff